Engineering Immunity: Biotechnological Paradigms in Modern Vaccine Development
Lydia Amarachi Onwuemelem *
Department of Medical Laboratory Science, University of Benin, Benin City, Edo State, Nigeria.
Mayowa Josiah Badmus
Faculty of Dentistry, Lagos University Teaching Hospital, Lagos, Nigeria.
Olukunle O. Akanbi
National Louis University, Tampa, FL, Hillsborough Ave, Tampa, FL 33634, United States.
Quadri Okiki N.
Northern Illinois University, Dekalb, Il, USA.
Alayande Opeoluwa Oluwatosin
Ogun-Oshun River Basin Development Authority, Nigeria.
Catherine Rono
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Oluwole Taiwo Fabiyi
Bioinformatics Department, University of Maryland Global Campus, USA.
*Author to whom correspondence should be addressed.
Abstract
The field of vaccine development has evolved in recent years, with the integration of biotechnology, which has brought about new models for engineering immunity. This paper examines the groundbreaking biotechnological advancements that have changed the course of vaccines in production, design, and efficacy. Modern technologies like mRNA, viral vectors, and synthetic biology have brought about more targeted and personalized immunization therapies. The molecular mechanisms behind these innovations were reviewed, including antigen presentation, immune modulation, and the optimization of adjuvants, as well as the challenges of ensuring long-term immunity. Ethical, regulatory, and logistical implications of these biotechnological tools were also considered in terms of pandemic and emerging infectious and chronic conditions. In addition, the promise and possibility of engineering immunity through biotechnology were highlighted, laying the foundation for the next generation of vaccines capable of addressing complex health challenges.
Keywords: Vaccine development, biotechnology, engineering immunity, messengerRNA vaccines, viral vector vaccines